{
    "id": "6429cfb557b1c7a315000005",
    "question": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "B",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, let's analyze the relevant information provided by the documents. The documents do not provide direct evidence on the impact of inhaled glucocorticoids on COVID-19 prevention. However, we can make an educated inference based on the general effects of glucocorticoids and the context of COVID-19. Glucocorticoids, such as inhaled glucocorticoids, are known for their anti-inflammatory properties. COVID-19 is primarily caused by the SARS-CoV-2 virus, which triggers an inflammatory response in the body. The use of glucocorticoids, especially in high doses and for extended periods, can suppress the immune system and potentially increase the risk of infections, including COVID-19. On the other hand, the documents do not provide information on the effectiveness of inhaled glucocorticoids in preventing COVID-19. The National Institutes of Health (NIH) and the World Health Organization (WHO) have provided guidance on the use of glucocorticoids during the COVID-19 pandemic, recommending their use only in severe cases or in patients with severe respiratory disease. The documents do not provide specific guidance on the use of inhaled glucocorticoids for COVID-19 prevention. In conclusion, based on the available information, it is not recommended to advise patients using inhaled glucocorticoids for asthma or COPD to stop these medications solely to prevent COVID-19, as there is no clear evidence to support this claim. The decision to continue or discontinue inhaled glucocorticoids should be made on a case-by-case basis, taking into account the individual patient's needs and the guidance of a healthcare professional.\", \"answer_choice\": \"B\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_20426",
            "title": "InternalMed_Harrison",
            "content": "Inhaled Glucocorticoids Although a recent trial demonstrated an apparent benefit from the regular use of inhaled glucocorticoids on the rate of decline of lung function, a number of other well-designed randomized trials have not. Patients studied included those with mild to severe airflow obstruction and current and ex-smokers. Patients with significant acute response to inhaled \u03b2 agonists were excluded from many of these trials, which may impact the generalizability of the findings. Their use has been associated with increased rates of oropharyngeal candidiasis and an increased rate of loss of bone density. Available data suggest that inhaled glucocorticoids reduce exacerbation frequency by ~25%. The impact of 1706 inhaled corticosteroids on mortality rates in COPD is controversial. A meta-analysis and several retrospective studies suggest a mortality benefit, but in a recently published randomized trial, differences in mortality rate approached, but did not reach, conventional"
        },
        {
            "id": "Pharmacology_Katzung_2108",
            "title": "Pharmacology_Katzung",
            "content": "Because of the efficacy and safety of inhaled corticosteroids, national and international guidelines for asthma management recommend their prescription for patients with persistent asthma who require more than occasional inhalations of a \u03b2 agonist for relief of symptoms. This therapy is continued for 10\u201312 weeks and then withdrawn to determine whether more prolonged therapy is needed; inhaled corticosteroids are not curative. In most patients, the manifestations of asthma return within a few weeks after stopping therapy even if they have been taken in high doses for 2 or more years. A prospective, placebo-controlled study of the early, sustained use of inhaled corticosteroids in young children with asthma showed significantly greater improvement in asthma symptoms, pulmonary function, and frequency of asthma exacerbations over the 2 years of treatment, but no difference in overall asthma control 3 months after the end of the trial. inhaled corticosteroids are thus properly labeled as"
        },
        {
            "id": "Pharmacology_Katzung_2173",
            "title": "Pharmacology_Katzung",
            "content": "down\u201d to a lower dose of inhaled corticosteroid (although still in combination with a long-acting \u03b2 agonist) once her condition stabilizes. They also need instruction on an action plan for managing severe symptoms. This can be as simple as advising that if the patient has a severe, frightening attack, she can take up to four puffs of albuterol every 15 minutes, but if the first treatment does not bring significant relief, she should take the next four puffs while on her way to an emergency department or urgent care clinic. She should also be given a prescription for prednisone, with instructions to take 40\u201360 mg orally for severe attacks, but not to wait for it to take effect if she remains severely short of breath even after albuterol inhalations. Asthma is a chronic disease, and good care requires close follow-up and creation of a provider-patient partnership for optimal management. If she has had several previous exacerbations, she should be considered a candidate for monoclonal"
        },
        {
            "id": "InternalMed_Harrison_20180",
            "title": "InternalMed_Harrison",
            "content": "Asthma in the Elderly Asthma may start at any age, including in elderly patients. The principles of management are the same as in other asthmatics, but side effects of therapy may be a problem, including muscle tremor with \u03b22-agonists and more systemic side effects with ICS. Comorbidities are more frequent in this age group, and interactions with drugs such as \u03b22-blockers, COX inhibitors, and agents that may affect theophylline metabolism need to be considered. COPD is more likely in elderly patients and may coexist with asthma. A trial of OCS may be very useful in documenting the steroid responsiveness of asthma."
        },
        {
            "id": "InternalMed_Harrison_20177",
            "title": "InternalMed_Harrison",
            "content": "Refractory asthma is difficult to control, by definition. It is important to check compliance and the correct use of inhalers and to identify and eliminate any underlying triggers. Low doses of theophylline may be helpful in some patients, and theophylline withdrawal has been found to worsen in many patients. Most of these patients will require maintenance treatment with oral corticosteroids, and the minimal dose that achieves satisfactory control should be determined by careful dose titration. Steroid-sparing therapies are rarely effective. In some patients with allergic asthma, omalizumab is effective, particularly when there are frequent exacerbations. Anti-TNF therapy is not effective in severe asthma and should not be used. A few patients may benefit from infusions of \u03b22-agonists. New therapies are needed for these patients, who currently consume a disproportionate amount of health care spending."
        },
        {
            "id": "InternalMed_Harrison_20425",
            "title": "InternalMed_Harrison",
            "content": "Beta Agonists These provide symptomatic benefit. The main side effects are tremor and tachycardia. Long-acting inhaled \u03b2 agonists, such as salmeterol or formoterol, have benefits comparable to ipratropium bromide. Their use is more convenient than short-acting agents. The addition of a \u03b2 agonist to inhaled anticholinergic therapy has been demonstrated to provide incremental benefit. A recent report in asthma suggests that those patients, particularly African Americans, using a long-acting \u03b2 agonist without concomitant inhaled corticosteroids have an increased risk of deaths from respiratory causes. The applicability of these data to patients with COPD is unclear."
        },
        {
            "id": "Pediatrics_Nelson_1765",
            "title": "Pediatrics_Nelson",
            "content": "and decrease systemic absorption from the gastrointestinal tract. Inhaled corticosteroids should be titrated to the lowest dose needed to maintain control of a child\u2019s asthma. For children with severe asthma, higher dose inhaled corticosteroids may be needed to minimize the oral corticosteroid dose, but other \u201cadd-on\u201d therapy should be considered (see the following sections)."
        },
        {
            "id": "InternalMed_Harrison_20440",
            "title": "InternalMed_Harrison",
            "content": "The role of pharmacotherapy in reducing exacerbation frequency is less well studied. Chronic oral glucocorticoids are not recommended for this purpose. Inhaled glucocorticoids reduce the frequency of exacerbations by 25\u201330% in most analyses. The use of inhaled glucocorticoids should be considered in patients with frequent exacerbations or those who have an asthmatic component, i.e., significant reversibility on pulmonary function testing or marked symptomatic improvement after inhaled bronchodilators. Similar magnitudes of reduction have been reported for anticholinergic and long-acting \u03b2-agonist therapy. The influenza vaccine has been shown to reduce exacerbation rates in patients with COPD. As outlined above, daily azithromycin administered to subjects with COPD and an exacerbation history reduces exacerbation frequency."
        },
        {
            "id": "Pharmacology_Katzung_2139",
            "title": "Pharmacology_Katzung",
            "content": "The long-acting antimuscarinic agents tiotropium and aclidinium have not yet earned a place in the treatment for asthma, although the addition of tiotropium to an ICS has been shown to be as effective as the addition of an LABA. As a treatment for COPD, these agents improve functional capacity, presumably through their action as bronchodilators, and reduce the frequency of exacerbations through currently unknown mechanisms. If asthmatic symptoms occur frequently, or if significant airflow obstruction persists despite bronchodilator therapy, inhaled corticosteroids should be started. For patients with severe symptoms or severe airflow obstruction (eg, FEV1 < 50% of predicted), initial treatment with a high dose of an ICS in combination with an LABA is appropriate. Once clinical improvement is noted, usually after 4\u20136 weeks, the dose of treatment should be stepped down to no more than is necessary to control symptoms and maintain pulmonary function."
        },
        {
            "id": "Pharmacology_Katzung_2110",
            "title": "Pharmacology_Katzung",
            "content": "Another approach to reducing the risk of long-term, twice-daily use of ICS is to administer them only intermittently, when symptoms of asthma flare. Taking a single inhalation of an ICS with each inhalation of a short-acting \u03b2-agonist reliever (eg, an inhalation of beclomethasone for each inhalation of albuterol) or taking a 5to 10-day course of twice-daily high-dose budesonide or beclomethasone when asthma symptoms worsen has been found to be nearly as effective as regular daily therapy in adults and children with mild to moderate asthma, although these approaches to treatment are neither endorsed by guidelines for asthma management nor approved by the FDA."
        },
        {
            "id": "Pediatrics_Nelson_1776",
            "title": "Pediatrics_Nelson",
            "content": "Inhaled corticosteroids are the preferred initial long-term control therapy for children of all ages (Fig. 78-3). Daily longterm control therapy is recommended for infants and young children 0 to 4 years of age who had four or more episodes of wheezing in the previous year that lasted more than 1 day, affected sleep, and who have a positive asthma predictive index. For children over 5 years of age with moderate persistent asthma, combining long-acting bronchodilators with low-tomedium doses of inhaled corticosteroids improves lung function and reduces rescue medication use. For children with severe persistent asthma, a high-dose inhaled corticosteroid and a long-acting bronchodilator are the preferred therapy. The guidelines also recommend that treatment be reevaluated within 2 to 6 weeks of initiating therapy. Once asthma is under control, control should be assessed on an ongoing basis every 1 to 6 months. The asthma should be well controlled for at least 3 months before stepping"
        },
        {
            "id": "Pharmacology_Katzung_2144",
            "title": "Pharmacology_Katzung",
            "content": "The concerns underlying the \u201cblack box\u201d warning have been assuaged by two large, placebo-controlled, double-blind FDA-mandated trials showing no significant increase in severe asthma exacerbations or asthma fatalities from the addition of an LABA to ICS treatment in patients with moderate to severe asthma. Despite these reassuring findings, patients prescribed combination treatment should also be provided with explicit instructions to continue use of a rapid-acting inhaled \u03b2 agonist, such as albuterol, for relief of acute symptoms and, as for all patients with asthma, to follow an explicit action plan for severe attacks."
        },
        {
            "id": "InternalMed_Harrison_20165",
            "title": "InternalMed_Harrison",
            "content": "Education Patients with asthma need to understand how to use their medications and the difference between reliever and controller FIGURE 309-8 Stepwise approach to asthma therapy according to the severity of asthma and ability to control symptoms. ICS, inhaled corticosteroids; LABA, long-acting \u03b22-agonist; OCS, oral corticosteroid. therapies. Education may improve compliance, particularly with ICS. 1679 All patients should be taught how to use their inhalers correctly. In particular, they need to understand how to recognize worsening of asthma and how to step up therapy. Written action plans have been shown to reduce hospital admissions and morbidity rates in adults and children, and are recommended particularly in patients with unstable disease who have frequent exacerbations."
        },
        {
            "id": "Pharmacology_Katzung_2109",
            "title": "Pharmacology_Katzung",
            "content": "frequency of asthma exacerbations over the 2 years of treatment, but no difference in overall asthma control 3 months after the end of the trial. inhaled corticosteroids are thus properly labeled as \u201ccontrollers.\u201d They are effective only so long as they are taken."
        },
        {
            "id": "Pediatrics_Nelson_1763",
            "title": "Pediatrics_Nelson",
            "content": "Inhaled corticosteroids are the most effective anti-inflammatory medications for the treatment of chronic, persistent asthma and are the preferred therapy when initiating longterm control therapy. Early intervention with inhaled corticosteroids reduces morbidity but does not alter the natural history of asthma. Regular use reduces airway hyperreactivity, the need for rescue bronchodilator therapy, risk of hospitalization, and risk of death from asthma. Inhaled corticosteroids are available as an inhalation aerosol, dry powder inhaler, and nebulizer solution."
        },
        {
            "id": "Pharmacology_Katzung_2170",
            "title": "Pharmacology_Katzung",
            "content": "Martinez FD: New insights into the natural history of asthma: Primary prevention on the horizon. J Allergy Clin Immunol 2011;128:939. Stein MM et al: Innate immunity and asthma risk in Amish and Hutterite farm children. N Engl J Med 2016;375:411. Treatment of COPD Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for Diagnosis, Management, and Prevention of COPD. http://www .goldcopd.org. Huisman EL et al: Comparative efficacy of combination bronchodilator therapies in COPD: A network meta-analysis. Int J Chron Obstruct Pulmon Dis 2015;10:1863. Kew KM, Dias S, Cates CJ: Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: A network meta-analysis. Cochrane Database Syst Rev 2014;1:CD010844. Niewoehner DE: Clinical practice. Outpatient management of severe COPD. N Engl J Med 2010;362:1407. Vogelmeier C et al: Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364:1093."
        },
        {
            "id": "Pharmacology_Katzung_2140",
            "title": "Pharmacology_Katzung",
            "content": "An issue for ICS treatment is patient adherence. Analysis of prescription renewals shows that only a minority of patients take corticosteroids regularly. This may be a function of a general \u201csteroid phobia\u201d fostered by emphasis in the lay press on the hazards of long-term oral corticosteroid therapy and by ignorance of the difference between glucocorticoids and anabolic steroids, taken to enhance muscle strength by now-infamous athletes. This fear of corticosteroid toxicity makes it hard to persuade patients whose symptoms have improved after starting treatment that they should continue it for protection against attacks. This context accounts for the interest in reports that instructing patients with mild but persistent asthma to take ICS therapy only when their symptoms worsen is nearly as effective in maintaining pulmonary function and preventing attacks as is taking the ICS twice each day."
        },
        {
            "id": "InternalMed_Harrison_20420",
            "title": "InternalMed_Harrison",
            "content": "Only three interventions\u2014smoking cessation, oxygen therapy in chronically hypoxemic patients, and lung volume reduction surgery in selected patients with emphysema\u2014have been demonstrated to influence the natural history of patients with COPD. There is 1705 currently suggestive, but not definitive, evidence that the use of inhaled glucocorticoids may alter mortality rate (but not lung function). All other current therapies are directed at improving symptoms and decreasing the frequency and severity of exacerbations. The institution of these therapies should involve an assessment of symptoms, potential risks, costs, and benefits of therapy. This should be followed by an assessment of response to therapy, and a decision should be made whether or not to continue treatment."
        },
        {
            "id": "Pharmacology_Katzung_2076",
            "title": "Pharmacology_Katzung",
            "content": "Long-acting \u03b22-selective agonists (LABA), with 12-hour durations of action, such as salmeterol and formoterol, were developed to facilitate asthma management. These drugs generally achieve their long duration of bronchodilating action as a result of high lipid solubility. This permits them to dissolve in the smooth muscle cell membrane in high concentrations or, possibly, attach to \u201cmooring\u201d molecules in the vicinity of the adrenoceptor. These drugs appear to interact with inhaled corticosteroids to improve asthma control. Because they have no anti-inflammatory action, they should not be used as monotherapy for asthma. Ultra-long-acting \u03b2 agonists, such as indacaterol, olodaterol, vilanterol, and bambuterol, need to be taken only once a day, but because their prolonged bronchodilation masks symptoms of bronchial inflammation, they should be used only in combination with an ICS for asthma. However, they may be used as mono-therapy for treatment of COPD."
        },
        {
            "id": "Pharmacology_Katzung_2157",
            "title": "Pharmacology_Katzung",
            "content": "The place of ICS therapy is less central to treatment of COPD than of asthma, in part because of its lower efficacy for this condition and in part because of reports of its use being associated with heightened risk of bacterial pneumonia. Its use is thus recommended only for patients with severe airflow obstruction or with a history of prior exacerbations. Acute exacerbations of COPD are a major driver of the morbidity, mortality, and health care costs of COPD. Because of the greater age of the patients affected and the prevalence of comorbidities, especially cardiovascular disease, the mortality of acute exacerbations is greater than that of exacerbation of asthma, but management does not differ greatly except in the routine use of antibiotics, which are given because exacerbations of COPD frequently involve bacterial infection of the lower airways."
        },
        {
            "id": "Pharmacology_Katzung_896",
            "title": "Pharmacology_Katzung",
            "content": "One of the most important uses of sympathomimetic drugs is in the therapy of asthma and chronic obstructive pulmonary disease (COPD; discussed in more detail in Chapter 20). Beta2-selective drugs (albuterol, metaproterenol, terbutaline) are used for this purpose to reduce the adverse effects that would be associated with \u03b21 stimulation. Short-acting preparations can be used only transiently for acute treatment of asthma symptoms. For chronic asthma treatment in adults, long-acting \u03b22 agonists should only be used in combination with steroids because their use in mono-therapy has been associated with increased mortality. Long-acting \u03b22 agonists are also used in patients with COPD. Indacaterol, olodaterol, and vilanterol, new ultralong \u03b22 agonists, have been approved by the FDA for once-a-day use in COPD. Nonselective drugs are now rarely used because they are likely to have more adverse effects than the selective drugs."
        },
        {
            "id": "Pharmacology_Katzung_2103",
            "title": "Pharmacology_Katzung",
            "content": "Clinical studies of corticosteroids consistently show them to be effective in improving all indices of asthma control: severity of symptoms, tests of airway caliber and bronchial reactivity, frequency of exacerbations, and quality of life. Because of severe adverse effects when given chronically, oral and parenteral corticosteroids are reserved for patients who require urgent treatment, ie, those who have not improved adequately with bronchodilators or who experience worsening symptoms despite high-dose maintenance therapy. For severe asthma exacerbations, urgent treatment is often begun with an oral dose of 30\u201360 mg prednisone per day or an intravenous dose of 0.5\u20131 mg/kg methylprednisolone every 6\u201312 hours; the dose is decreased after airway obstruction has improved. In most patients, systemic corticosteroid therapy can be discontinued in 5\u201310 days, but symptoms may worsen in other patients as the dose is decreased to lower levels."
        },
        {
            "id": "InternalMed_Harrison_20164",
            "title": "InternalMed_Harrison",
            "content": "an add-on therapy, but these are less effective than LABA. In patients with severe asthma, low-dose oral theophylline is also helpful, and when there is irreversible airway narrowing, the long-acting anticholinergic tiotropium bromide may be tried. If asthma is not controlled despite the maximal recommended dose of inhaled therapy, it is important to check compliance and inhaler technique. In these patients, maintenance treatment with an OCS may be needed, and the lowest dose that maintains control should be used. Occasionally omalizumab may be tried in steroid-dependent asthmatics who are not well controlled. Once asthma is controlled, it is important to slowly decrease therapy in order to find the optimal dose to control symptoms."
        },
        {
            "id": "Pharmacology_Katzung_2158",
            "title": "Pharmacology_Katzung",
            "content": "Because of their importance in driving the morbidity and mortality of COPD, much attention has been paid to approaches to prevention of COPD exacerbations. For patients with a history of two or more exacerbations, daily treatment with an ICS is appropriate, and a recent large study showed significant reduction in exacerbation frequency from daily treatment with azithromycin. An innovative, although initially counterintuitive, hypothesis is now also under examination: that treatment with the selective \u03b21-receptor antagonist, metoprolol succinate, will reduce exacerbations in patients with moderate to severe COPD. The hypothesis is counterintuitive because nonselective \u03b2-blocker therapy so predictably worsens airflow obstruction in asthmatic patients that it has long been considered contraindicated for patients with COPD. Several developments and observations have changed this view. These include the development of selective \u03b21-receptor antagonists and the recognition that the use of"
        },
        {
            "id": "Pharmacology_Katzung_2104",
            "title": "Pharmacology_Katzung",
            "content": "Inhalational treatment is the most effective way to avoid the systemic adverse effects of corticosteroid therapy. The introduction of ICS such as beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, mometasone, and triamcinolone has made it possible to deliver corticosteroids to the airways with minimal systemic absorption. An average daily dose of 800 mcg of inhaled beclomethasone is equivalent to about 10\u201315 mg/d of oral prednisone for the control of asthma, with far fewer systemic effects. Indeed, one of the cautions in switching patients from chronic oral to ICS therapy is to taper oral therapy slowly to avoid precipitation of adrenal insufficiency. In patients requiring continued prednisone treatment despite standard doses of an ICS, higher inhaled doses are often effective and enable tapering and discontinuing prednisone treatment. Although these high doses of inhaled steroids may cause mild adrenal suppression, the risks of systemic toxicity from their chronic use"
        },
        {
            "id": "InternalMed_Harrison_20170",
            "title": "InternalMed_Harrison",
            "content": "SPECIAL CONSIDERATIONS Refractory Asthma Although most patients with asthma are easily controlled with appropriate medication, a small proportion of patients (approximately 5\u201310% of asthmatics) are difficult to control despite maximal inhaled therapy. Some of these patients will require maintenance treatment with OCS. In managing these patients, it is important to investigate and correct any mechanisms that may be aggravating asthma. There are two major patterns of difficult asthma: some patients have persistent symptoms and poor lung function, despite appropriate therapy, whereas others may have normal or near-normal lung function but intermittent, severe (sometimes life-threatening) exacerbations."
        },
        {
            "id": "Pediatrics_Nelson_1769",
            "title": "Pediatrics_Nelson",
            "content": "Long-Acting \u03b22-Agonists Long-acting \u03b22-agonists, formoterol and salmeterol, have twice-daily dosing and relax airway smooth muscle for 12 hours but do not have any significant anti-inflammatory effects. Adding a long-acting bronchodilator to inhaled corticosteroid therapy is more beneficial than doubling the dose of inhaled corticosteroids. Multiple formulations are available. Formoterol is approved for use in children older than 5 years of age for maintenance asthma therapy and for prevention of exercise-induced asthma. It has a rapid onset of action similar to albuterol (15 minutes). Salmeterol is approved for children 4 years of age or older and has an onset of 30 minutes. Because combination agents administer two medications simultaneously, compliance is generally improved."
        },
        {
            "id": "Pharmacology_Katzung_2132",
            "title": "Pharmacology_Katzung",
            "content": "National and international guidelines for asthma emphasize the need for adjusting the intensity of asthma therapy to the underlying severity of the disease and the level of control achieved by the patient\u2019s current treatment (https://www.nhlbi.nih.gov/ health-pro/guidelines/current/asthma-guidelines; ginasthma.org). An underlying principle common to these guidelines is that asthma should be considered in two time domains. In the present domain, asthma is important for the symptoms and impairments it causes\u2014cough, nocturnal awakenings, and shortness of breath that interfere with the ability to exercise or to pursue desired activities. For mild asthma, occasional inhalation of a bronchodilator may be all that is needed to control these symptoms. For more severe asthma, treatment with a long-term controller, like an ICS, is necessary to relieve symptoms and restore function. The second domain of asthma is the risk it presents of future events, such as exacerbations or progressive loss of"
        },
        {
            "id": "Pharmacology_Katzung_2099",
            "title": "Pharmacology_Katzung",
            "content": "daily. Daily inhalation of tiotropium has been shown not only to improve functional capacity of patients with COPD, but also to reduce the frequency of exacerbations of their condition. These drugs have not yet been approved as maintenance treatment for asthma, but the addition of tiotropium is no less effective than addition of an LABA in asthmatic patients insufficiently controlled by ICS therapy alone."
        },
        {
            "id": "Pharmacology_Katzung_2052",
            "title": "Pharmacology_Katzung",
            "content": "Until recently, the entire range of asthma severity was regarded as eminently treatable, because treatments for quick relief of symptoms of acute bronchoconstriction (\u201cshort-term relievers\u201d) and treatments for reduction in symptoms and prevention of attacks, especially using inhaled corticosteroids (\u201clong-term controllers\u201d), had been shown to be effective in many large, well-designed randomized clinical trials, pragmatic clinical trials, observational studies, and evidence-based reviews. The persistence of high medical costs for asthma, driven largely by the costs of emergency department and hospital treatment of asthma exacerbations, was thus believed to reflect underutilization of the treatments available. Reconsideration of this view was driven by recognition that the term \u201casthma\u201d is applied to a variety of different disorders sharing common clinical features but fundamentally different pathophysiologic mechanisms. Attention has thus turned to the possibility that there are"
        },
        {
            "id": "Pharmacology_Katzung_2155",
            "title": "Pharmacology_Katzung",
            "content": "Although asthma and COPD are both characterized by airway inflammation, reduction in maximum expiratory flow, and episodic exacerbations of airflow obstruction, most often triggered by viral respiratory infection, they differ in many important respects. Compared to asthma, COPD occurs in older patients, is associated with neutrophilic rather than eosinophilic inflammation, is poorly responsive even to high-dose ICS therapy, and is associated with progressive, inexorable loss of pulmonary function over time, especially with continued cigarette smoking."
        },
        {
            "id": "InternalMed_Harrison_20163",
            "title": "InternalMed_Harrison",
            "content": "Stepwise Therapy For patients with mild, intermittent asthma, a short-acting \u03b22-agonist is all that is required (Fig. 309-8). However, use of a reliever medication more than twice a week indicates the need for regular controller therapy. The treatment of choice for all patients is an ICS given twice daily. It is usual to start with an intermediate dose (e.g., 200 \u03bcg bid of beclomethasone dipropionate [BDP]) or equivalent and to decrease the dose if symptoms are controlled after 3 months. If symptoms are not controlled, a LABA should be added, which is most conveniently given by switching to a combination inhaler. The dose of controller should be adjusted accordingly, as judged by the need for a rescue inhaler. Low doses of theophylline or an antileukotriene may also be considered as an add-on therapy, but these are less effective than LABA. In patients with severe asthma, low-dose oral theophylline is also helpful, and when there is irreversible airway narrowing, the long-acting"
        }
    ],
    "scores": [
        0.03731975327411563,
        0.03509107098577579,
        0.034790733495232956,
        0.03155296052213706,
        0.03009497876754514,
        0.029755089739199908,
        0.02959298628802345,
        0.029413649531715023,
        0.029076501481374015,
        0.028945775077506602,
        0.02885111161941527,
        0.028586347871185233,
        0.02582256852058832,
        0.025669017329809415,
        0.025254885301614273,
        0.025008197355897314,
        0.024505293083454907,
        0.024023199023199025,
        0.023566908085631385,
        0.023136273589823793,
        0.022907926307370666,
        0.022381395861725092,
        0.02189770312345557,
        0.021817410966647827,
        0.021643795967267468,
        0.02159340505678286,
        0.02157543508445183,
        0.020965349787542945,
        0.020883249689709137,
        0.020721950677241287,
        0.020507817385866167,
        0.020493442499623853
    ]
}